Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27268924 | 0.79 | HPGD (0.33) | HPGDKDM4EALDH1A1 | |
| SCHEMBL2374738 | 0.77 | CYP2C9 (0.33) | HPGDKDM4EALDH1A1 | |
| SCHEMBL27269104 | 0.75 | SMN1; SMN2 (0.33) | HPGDKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL27269071 | 0.75 | SMN1; SMN2 (0.33) | HPGDKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL445583 | 0.74 | APP (0.35) | HPGDKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL15434719 | 0.74 | BACE1 (0.47) | — | |
| SCHEMBL1465368 | 0.74 | BACE1 (0.47) | — | |
| SCHEMBL28941461 | 0.74 | CHRNA7 (0.35) | KMT2A | |
| SCHEMBL28749072 | 0.74 | CHRNA7 (0.35) | KMT2A | |
| SCHEMBL29689597 | 0.74 | CHRNA7 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | HPGD 303/4885KDM4E 4178/4885MEN1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.